Researchers have come u with a new treatment strategy to combat cancer. Researchers at the University of Michigan Comprehensive Cancer Centre have discovered that pushing the cancerous cells into over drive results in their self-destruction.
And this is possible by using bortezomib, a promising cancer drug, which helps to strike a blow against melanoma tumour cells by revving up the action of a cancer-promoting gene. Researchers discovered that bortezomib, a drug approved by the FDA to treat advanced multiple myeloma, is able to selectively inhibit melanoma tumour cells because it causes the c-MYC oncogene to overproduce a cell-death promoter called NOXA.
Their findings place c-MYC and NOXA, well studied among cancer researchers, in a new light. Our data suggest a different approach to treat cancer, said Maria S. Soengas, Ph.D., the senior author of the study. Many cancer treatments aim to block specific oncogenes, genes that wreak havoc with the normal signals that dictate when cells multiply and die.
The thinking is that if oncogenes are disabled, cancer cells cant proliferate uncontrollably and spread. However, researchers know that oncogenes can play dual roles: They can cause tumour cells to rapidly divide, but can also step up programmed cell death, or apoptosis. Therefore, an alternative treatment could be to actually exacerbate oncogene function, to promote such a dysregulation of cell cycle progression and activation of apoptotic proteins that tumour cells ultimately die, Soengas said.